Albiruni R. Abdul Razak

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 992 citations

Medicine, Oncology, Pharmacotherapy +17

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2017 · 508 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

William D. Tap, Andrew J. Wagner, Patrick Schöffski et al. · JAMA · 2020 · 301 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Tracy Stockley, Amit M. Oza, Hal K. Berman et al. · Genome Medicine · 2016 · 285 citations · Full text

Medicine, Molecular Medicine, Oncology +17